内生レトロウイルスに対する抗体は,肺がんの免疫療法を促進する
Kevin W Ng1, Jesse Boumelha2, Katey S S Enfield3
1Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
Nature
|April 12, 2023
まとめ
肺がんにおける三次リンパ性構造 (TLS) は,免疫療法に対するよりよい反応と相関しています. 免疫療法によって増強された内生レトロウイルス (ERV) 抗体は,抗腫瘍活性を促進し,有効性のためにTLSを必要とします.
科学分野:
- 免疫学
- 腫瘍学
- 癌 研究
背景:
- 三次リンパ性構造 (TLS) は,固体腫瘍で発見され,患者の生存率と免疫チェックポイントブロック (ICB) に対する応答の改善と相関しています.
- TLSと免疫療法の反応を結びつけるメカニズムは不明である.
- 肺アデノカルシノーマはTLS内のB細胞反応を示します.
研究 の 目的:
- 肺がんにおけるB細胞反応の役割と,三次リンパ性構造 (TLS) と免疫療法との関連を調査する.
- 肺腺がんにおける抗腫瘍抗体の特定の標的を特定する.
- TLSが免疫療法の有効性に影響を与えるメカニズムを解明する.
主な方法:
- 肺がん患者コホート (TRACERx 421) と免疫性マウスモデルを分析した.
- 腫瘍結合試験を用いた抗体標的の特定
- B細胞の反応,TLSの形成,および抗腫瘍活動の評価
- 免疫療法 (ICB) と標的型KRAS (G12C) 抑制効果の評価
主要な成果:
- 肺アデノカルシノーマは,内生レトロウイルス (ERV) 包膜グリコプロテインを主要標的にして,生殖中心の反応と腫瘍結合抗体を誘発する.
- ERVを標的とするB細胞の反応は,ICBとKRAS ((G12C) 抑制によって強化される.
- ERV反応性抗体は抗腫瘍活性を示し,マウスの生存率を向上させる.
- ERV発現は,ヒト肺腺がんにおけるICBのアウトカムを予測する.
- 効果的な免疫療法にはCXCL13依存のTLS形成が必要であり,CXCL13治療は抗腫瘍免疫を強化する.
結論:
- 内生レトロウイルス (ERV) を標的にするB細胞の反応は,肺腺がんにおける抗腫瘍活動において極めて重要です.
- CXCL13によって引き起こされる三次リンパ性構造 (TLS) の形成は,効果的な免疫療法にとって不可欠である.
- ERV特異的なB細胞反応を標的とし,TLS形成を促進することは,肺がんの潜在的な治療戦略です.
関連する概念動画
Mechanisms of Retrovirus-induced Cancers
5.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.2K
Tumor Immunotherapy
596
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
596
Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
Retrovirus Life Cycles
46.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.3K
Cancer Vaccines
456
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
456


